Topical and intralesional therapies for in-transitmelanoma

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2019-09-02 DOI:10.2217/mmt-2019-0008

M. Henderson

引用次数: 2

Abstract

This report surveys the role of topical and intralesional agents in the management of in-transit melanoma. The extent and progression of in-transit disease is highly variable and many patients can have a protracted period of locoregional control. These agents are useful in the management of patients who have progressed beyond local surgical excision in whom more aggressive therapies, such as isolated limb infusion or use of talimogene laherparepvec, are not appropriate or have failed. In general, these agents are modestly effective and associated with frequent but only minor toxicity. As the mechanism of action of many of these agents includes initiation of a local immune response, combinations with immune checkpoint inhibitors are currently being explored.

查看原文本刊更多论文

转移期黑色素瘤的局部和病灶内治疗

本报告调查了局部和局部药物在运输中的黑色素瘤管理中的作用。过境疾病的范围和进展是高度可变的，许多患者可以有一个长期的局部区域控制。这些药物对于局部手术切除后进展的患者是有用的，在这些患者中，更积极的治疗，如孤立肢体输注或使用talimogene laherparepvec，是不合适的或失败的。一般来说，这些药物的效果一般，并伴有频繁但仅轻微的毒性。由于许多这些药物的作用机制包括启动局部免疫反应，目前正在探索与免疫检查点抑制剂的联合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.